Literature DB >> 6207822

Characteristics of the epitope of leukotriene B4 recognized by a highly specific mouse monoclonal antibody.

J Y Lee, T Chernov, E J Goetzl.   

Abstract

Mouse monoclonal IgG2b antibodies to leukotriene B4 bind [3H]leukotriene B4 with an affinity one-thirtieth to one-third that of different rabbit antibodies to leukotriene B4. The concentrations of related ligands required to inhibit by 50% the binding of [3H]leukotriene B4 define cross-reactivities of approximately 100% for carboxyl-derivatives of leukotriene B4, 10% for 12(S)-leukotriene B4 and 8 cis-leukotriene B4, which were not distinguished from leukotriene B4 by polyclonal antibodies, 3-5% for the two isomers of 6 trans-leukotriene B4, 5% for 20-OH-leukotriene B4 and 20-COOH-leukotriene B4, and less than 1% for other leukotrienes, mono-hydroxy-eicosatetraenoic acids, and the two leukotriene B4-like isomers of 8, 15-di-hydroxy-eicosatetraenoic acid. Thus the monoclonal combining site is highly specific for the di-hydroxy-triene portion of leukotriene B4.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6207822     DOI: 10.1016/s0006-291x(84)80225-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Down-regulation of receptor antigen in leukotriene B4-induced chemotactic deactivation of human polymorphonuclear leucocytes.

Authors:  J M Boggs; C H Koo; E J Goetzl
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

2.  Accumulation of leukotriene C4 and histamine in human allergic skin reactions.

Authors:  S F Talbot; P C Atkins; E J Goetzl; B Zweiman
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

3.  Mouse monoclonal antibody to a latent epitope of leucocyte receptors for leukotriene B4.

Authors:  J P Harvey; C H Koo; J M Boggs; R N Young; E J Goetzl
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

4.  Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC).

Authors:  C E Sigal; F H Valone; M J Holtzman; E J Goetzl
Journal:  J Clin Immunol       Date:  1987-03       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.